<DOC>
	<DOCNO>NCT01437267</DOCNO>
	<brief_summary>This phase 2 trial aim obtain information safety immunogenicity Vi-CRM197 child infants various age group Philippines Typhoid Fever highly endemic efficacious vaccine disease much need .</brief_summary>
	<brief_title>Safety Immunogenicity Vi-CRM197 Vaccine Against S. Typhi Children , Older Infants Infants</brief_title>
	<detailed_description />
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Subjects belong 3 age group enrol trial : child ( 24 59 month age enrollment ) , old infant ( 9 12 month age enrollment ) infant ( 6 week age enrolment ) . Written inform consent obtain parents/ guardian enrollment trial . Infants vaccinate BCG HBV birth OPV time since birth enrol trial , infant receive DTwP+HBV+Hib due 6 week age per local EPI schedule enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>